The activity of ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa.

The ceftazidime/avibactam presented the higher susceptibility profile following colistin/polymyxin (96%), with 73% of susceptibility. In resume, ceftazidime/avibactam is an option for the treatment of carbapenem-resistant I P. aeruginosa i in Brazil. To the Editor, In this journal attempts to circumvent carbapenem resistance of I Pseudomonas aeruginosa i were recently reported [[1]]. [Extracted from the article]